开年首炸！卫健委发文，生物制造原料获批！伊利、蒙牛、华熙等上市龙头迎利好！

Group 1 - The article highlights the emergence of new probiotic products, particularly the approval of Bifidobacterium longum subsp. infantis YLGB-1496 as a new food ingredient for infants, which is now included in the list of approved strains for infant food in China and recognized by the European Food Safety Authority [3][4]. - The product is derived from breast milk and has been integrated into various core products of Yili, including fruit and vegetable probiotic drinks and yogurt, demonstrating its versatility across different food forms [6]. - Mengniu's subsidiary has achieved approval for three major Human Milk Oligosaccharides (HMOs) products, marking a significant milestone in the infant formula market [7][8]. Group 2 - The article discusses the global first approval of 2'-fucosyllactose (2'-FL) for use in infant formula, with the product being developed by Mengniu in collaboration with a biotechnology firm [9][8]. - A new production method utilizing yeast for HMO production has been validated, with a theoretical output of 150 tons per year, which is both safe and environmentally friendly [11][13]. - Huaxi Biological has entered the HMO market with the approval of Lacto-N-neotetraose (LNnT) as a food nutrition enhancer, further expanding its portfolio of HMO products [14][15].